Answering Key Questions for the Successful Management of Patients With Insomnia

Release date: March 15, 2016
Expiration date: March 15, 2017
Last review: February 8, 2016
Estimated time to complete activity: 1 hour

This activity is jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and MedEdicus LLC.


This activity is supported by an independent educational grant from Merck & Co., Inc.

Presented by


Moderator

Larry Culpepper, MD, MPH
Chief, Department of Family Medicine
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Massachusetts

Faculty

Angela Golden, DNP, FNP-C, FAANP
Owner
NP from Home, LLC
Munds Park, Arizona
Assistant Professor (Retired)
Northern Arizona University
Flagstaff, Arizona

Paul P. Doghramji, MD, FAAFP
Senior Family Physician
Collegeville Family Practice
Medical Director, Health Services
Ursinus College
Collegeville, Pennsylvania

Target Audience

This activity is intended for primary care physicians, nurse practitioners, registered nurses, and physician assistants.

Learning Objectives

Upon completion of this activity, participants will have improved their ability to:

  1. Evaluate the mechanism of action, efficacy, and safety of pharmacologic management for insomnia disorder
  2. Select appropriate initial doses and adjust dose levels based on response to pharmacologic therapy for patients with insomnia
  3. Develop individualized long-term treatment plans for patients with insomnia

 

System Requirements for Digital Edition

If you are viewing this activity online please ensure the computer you plan to use meets the following requirements:

  • Operating System: Windows or Macintosh
  • Media Viewing Requirements: Flash Player or Adobe Reader
  • Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
  • A good Internet connection

 

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and MedEdicus LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Larry Culpepper, MD, MPH, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (e.g., advisory boards): Forest Laboratories, Inc; H Lundbeck A/S; Ironwood; Merck & Co, Inc; Shire; Sunovion; and Takeda Pharmaceuticals USA, Inc; Ownership Interest (stocks, stock options or other ownership interest excluding diversified mutual funds): M-3 Information, LLC; Royalty: UpToDate and Oxford University Press; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers' bureaus): Elsevier Press; Other: Editor in Chief of the Primary Care Companion for CNS Diseases.

Paul P. Doghramji, MD, FAAFP, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees (e.g., advisory boards): AstraZeneca; Iroko Pharmaceuticals, LLC; Merck & Co, Inc; and Teva Pharmaceutical Industries Ltd; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): AstraZeneca; Merck & Co, Inc; Takeda Pharmaceuticals USA, Inc; and Teva Pharmaceutical Industries Ltd; Ownership Interest (stocks, stock options or other ownership interest excluding diversified mutual funds): Pfizer Inc.

Angela Golden, DNP, FNP-C, FAANP, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consulting Fees (e.g., advisory boards): Merck & Co, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner did not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following MedEdicus planners and managers, Robert Geist IV, MD, Diane McArdle, PhD, Michelle Ong, and Cynthia Tornallyay, RD, MBA, CHCP, have no real or apparent conflicts of interest to report.

Method of Participation and Request for Credit

There are no fees for participating in and receiving CME/CE credit for this activity. During the period March 15, 2016, through March 15, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, a certificate will be made available immediately.

Media

Internet

Disclosure of Unlabeled Use

This educational activity might contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This CME/CE activity is copyrighted to MedEdicus LLC © 2016. All rights reserved. Project 96


click me